Sera Prognostics Inc (SERA)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $79.94M
Last updated: Nov 17, 2026 at 4:10 PM ET
Sera Prognostics Inc (SERA) Statistics
Sera Prognostics (SERA) has a market cap of $79.94M and an enterprise value of $75.95M. It kept -34866.67% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 4.99% below the market cap, as cash exceeds debt.
| Market Cap | $79.94M |
|---|---|
| Enterprise Value | $75.95M |
| Latest price (Nov 17, 2026) | $2.00 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| Forward P/S | 399.7x |
|---|---|
| P/B Ratio | 1.9x |
| P/TBV Ratio | 2.0x |
Price Statistics
The stock is down 32.43% over 52 weeks and trades 1.96% below its 50-day average.
| Beta (1Y) | 0.47 |
|---|---|
| 52-Week Change | -32.43% |
| 1-Month Change | -1.48% |
| 3-Month Change | +0.50% |
| 6-Month Change | +14.94% |
| 5-Year Change | -80.25% |
| Total Return (1Y) | -32.43% |
| Total Return (3Y CAGR) | +4.55% |
| Total Return (5Y CAGR) | -28.30% |
| Return vs SPY (1Y) | -47.46% |
| Max Drawdown (1Y) | -56.91% |
| Max Drawdown (3Y) | -87.25% |
| Sharpe Ratio (1Y) | -0.67 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $2.04 |
| 200-Day Average | $2.06 |
| 52-Week Range | $1.56 to $3.85 |
| RSI (14 Days) | 47.9 |
| Average Volume (20 Days) | 43.67K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.88x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.88x |
|---|---|
| Quick Ratio | 1.88x |
| Debt / Equity | 0.00x |
| Interest Coverage | -4780.71x |
Returns and Efficiency
Return on equity is -63.83% over the last 12 months, against a 5-year average of -46.55%.
| Return on Equity (ROE) | -63.83% |
|---|---|
| Return on Assets (ROA) | -41.85% |
| Return on Capital Employed (ROCE) | -60.35% |
| ROE (5Y Average) | -46.55% |
| ROA (5Y Average) | -35.28% |
| ROIC (5Y Average) | -33.44% |
| Asset Turnover | 0.00x |
| Receivables Turnover | 7.11x |
Scores
SERA has an Altman Z-Score of -4.75, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -4.75 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $96.00K over the last 12 months is up 1.05% from the 12 months before.
| Revenue | $96.00K |
|---|---|
| Revenue Growth (YoY) | +1.05% |
| Gross Profit | $96.00K |
| Operating Income | -$37.20M |
| Pretax Income | -$33.47M |
| Net Income | -$33.47M |
| EBITDA | -$32.37M |
| EBIT | -$33.47M |
| Reported EPS (TTM) | -$0.67 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 65.57% of the $79.98M in total assets.
| Cash and Equivalents | $3.99M |
|---|---|
| Total Debt | $0 |
| Net Cash | $3.99M |
| Net Cash Per Share | $0.08 |
| Working Capital | $21.69M |
| Shareholder Equity | $52.44M |
| Book Value Per Share | $1.03 |
| Tangible Book Value | $51.58M |
| Tangible Book Per Share | $1.02 |
| Total Assets | $79.98M |
| Total Liabilities | $27.54M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $488.00K of capital spending, operating cash flow left -$28.99M of free cash flow.
| Operating Cash Flow | -$28.50M |
|---|---|
| Capital Expenditures | $488.00K |
| Free Cash Flow | -$28.99M |
| FCF Per Share | -$0.75 |
| Depreciation and Amortization | $1.10M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -38755.21%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -38755.21% |
| Pretax Margin | -34866.67% |
| Net Margin | -34866.67% |
| EBITDA Margin | -33715.63% |
| EBIT Margin | -34859.38% |
| FCF Margin | -30198.96% |
Growth
Revenue fell 32.89% a year over 3 years.
| Revenue Growth (3Y CAGR) | -32.89% |
|---|---|
| Revenue Growth (5Y CAGR) | +26.51% |
| Book Value Per Share Growth (2Y CAGR) | -17.81% |
| Tangible Book Per Share Growth (2Y CAGR) | -18.30% |
Dividends and Yields
SERA does not pay a dividend. Its free cash flow yield is -28.54%.
| FCF Yield | -28.54% |
|---|---|
| Buyback Yield | -0.13% |
| Shareholder Yield | -0.13% |
Analyst Forecast
Consensus estimates put revenue growth at 405.12% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +405.12% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SERA
What is SERA's market cap?
Sera Prognostics has a market cap of $79.94M. Its enterprise value, which adds debt and subtracts cash, is $75.95M.
How many shares of SERA are outstanding?
Sera Prognostics has 50.79M shares outstanding. The count is up 2.55% from a year earlier.
Does SERA pay a dividend?
No. Sera Prognostics does not pay a dividend.
How much debt does SERA have?
Sera Prognostics has $0 of total debt and $3.99M of cash and equivalents, a net cash position of $3.99M.
SERA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors